ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
Development of disease-modifying therapies for early-stage type 1 diabetes: insights from the EDENT1FI project
Felix Reschke 1 , Elisabeth Niemoeller 2 , Jurgen Vercauteren 3 , Erik Christiansen 4 , Jessica Dunne 4 , Laura Knecht 5 , Esther Latres 6 , Julia Mader 7 , Vit Neumann 8 , Thomas Pieber 7 , Rebecca Playle 9 , Peter Taylor 9 , Julia Townson 9 & Colin Dayan 9
1Children`s Hospital AUF DER BULT, Centre for Endocrinology, Diabetology, Metabolism & Clinical Research, Hanover, Germany; 2Sanofi, Frankfurt, Germany; 3KU Leuven, Leuven, Belgium; 4Novo Nordisk, Soeborg, Denmark; 5Sanofi, Bridgewater, United States; 6Breakthrough T1D, New York City, United States; 7Medical University of Graz, Graz, Austria; 8Charles University and University Hospital Motol, Prague, Czech Republic; 9Cardiff University, Cardiff, United Kingdom
JOINT3393
Background and Objectives: The EDENT1FI project aims to advance early diagnosis and intervention for Type 1 Diabetes (T1D), focusing on reducing the progression of the disease and delaying insulin therapy. This project involves screening 200,000 children in Europe for islet autoantibodies, identifying early-stage T1D, and offering targeted disease-modifying therapies (DMTs) to preserve beta-cell function. WP4, dedicated to developing protocols or administering DMTs, investigates interventions aimed at halting or slowing beta-cell destruction, with the potential to dramatically alter the clinical course of T1D.
Methods: The EDENT1FI initiative includes six work packages (WP). WP1 handles screening programs across Europe, WP2 explores psychosocial impacts, WP3 establishes follow-up protocols, WP4 focuses on the development and testing of DMTs, WP5 manages communication strategies, and WP6 ensures project governance. WP4’s adaptive trial designs aim to test multiple DMTs, incorporating biomarkers such as C-peptide and glucose tolerance to evaluate efficacy in preserving beta-cell function and delaying progression to insulin dependency. The data is collected from multiple countries, ensuring a comprehensive understanding of the disease progression.
Results: WP4 is developing innovative therapeutic strategies using adaptive trials to assess the efficacy of DMTs for T1D. Key biomarkers, including C-peptide and glucose levels, will be used to identify children and adolescents who are at risk of rapid disease progression. Preliminary results suggest that DMTs can potentially preserve beta-cell function, delaying the onset of insulin dependence. By using adaptive trial designs, WP4 can provide insights into the most effective interventions for managing early-stage T1D.
Conclusion: EDENT1FI, through WP4, establishes the framework to support future disease-modifying therapy trials that could revolutionize the treatment of early-stage T1D. By delaying insulin therapy and preserving beta-cell function, these therapies have the potential to improve long-term health outcomes for children and adolescents with T1D. This collaborative effort leverages advanced biomarkers, adaptive trial designs, and international expertise to offer a more personalized and effective approach to managing early-stage T1D.
Disclaimer: Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more